Sareum Hldgs Plc (SAR) - Total Liabilities

Latest as of June 2025: £1.95 Million GBP ≈ $2.62 Million USD

Based on the latest financial reports, Sareum Hldgs Plc (SAR) has total liabilities worth £1.95 Million GBP (≈ $2.62 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Sareum Hldgs Plc - Total Liabilities Trend (2004–2025)

This chart illustrates how Sareum Hldgs Plc's total liabilities have evolved over time, based on quarterly financial data. See Sareum Hldgs Plc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Sareum Hldgs Plc Competitors by Total Liabilities

The table below lists competitors of Sareum Hldgs Plc ranked by their total liabilities.

Company Country Total Liabilities
Mount Ridley Mines Ltd
AU:MRD
Australia AU$52.21K
Ropharma Bras
RO:RPH
Romania RON688.42 Million
Mirae ING Co Ltd
KO:007120
Korea ₩21.87 Billion
Cubic Digital Technology Co Ltd
SHE:300344
China CN¥144.52 Million
Generic Engineering Construction and Projects Limited
NSE:GENCON
India Rs1.89 Billion
Enero Group Ltd
AU:EGG
Australia AU$65.79 Million
Formosa Ingredient Factory PT Tbk
JK:BOBA
Indonesia Rp25.66 Billion
SynCore Biotechnology Co Ltd
TWO:4192
Taiwan NT$14.88 Million

Liability Composition Analysis (2004–2025)

This chart breaks down Sareum Hldgs Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SAR market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.17 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.86 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sareum Hldgs Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sareum Hldgs Plc (2004–2025)

The table below shows the annual total liabilities of Sareum Hldgs Plc from 2004 to 2025.

Year Total Liabilities Change
2025-06-30 £1.95 Million
≈ $2.62 Million
+199.08%
2024-06-30 £653.00K
≈ $876.92K
-24.68%
2023-06-30 £867.00K
≈ $1.16 Million
+90.55%
2022-06-30 £455.00K
≈ $611.02K
+60.12%
2021-06-30 £284.15K
≈ $381.59K
+43.12%
2020-06-30 £198.54K
≈ $266.62K
+35.13%
2019-06-30 £146.93K
≈ $197.31K
-19.91%
2018-06-30 £183.46K
≈ $246.36K
+17.95%
2017-06-30 £155.53K
≈ $208.87K
+56.24%
2016-06-30 £99.55K
≈ $133.69K
+47.61%
2015-06-30 £67.44K
≈ $90.57K
+2.48%
2014-06-30 £65.81K
≈ $88.38K
-17.66%
2013-06-30 £79.92K
≈ $107.33K
-34.96%
2012-06-30 £122.87K
≈ $165.01K
+26.67%
2011-06-30 £97.00K
≈ $130.26K
0.00%
2010-06-30 £97.00K
≈ $130.26K
+86.54%
2009-06-30 £52.00K
≈ $69.83K
-88.15%
2008-06-30 £439.00K
≈ $589.54K
-62.70%
2007-06-30 £1.18 Million
≈ $1.58 Million
+102.93%
2006-06-30 £580.00K
≈ $778.89K
+22.88%
2005-06-30 £472.00K
≈ $633.85K
-41.73%
2004-06-30 £810.00K
≈ $1.09 Million
--

About Sareum Hldgs Plc

LSE:SAR UK Biotechnology
Market Cap
$3.99 Billion
£2.97 Billion GBP
Market Cap Rank
#24608 Global
#232 in UK
Share Price
£21.50
Change (1 day)
-2.27%
52-Week Range
£12.00 - £27.50
All Time High
£457.50
About

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical st… Read more